Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, People's Republic of China; Institute of Nephrology, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, People's Republic of China; Institute of Nephrology, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China; Department of Nephrology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, People's Republic of China.
Biochim Biophys Acta Mol Basis Dis. 2024 Mar;1870(3):167039. doi: 10.1016/j.bbadis.2024.167039. Epub 2024 Jan 27.
Chronic kidney disease (CKD) is a prevalent renal disorder with various risk factors. Emerging evidence indicates that the transcriptional factor CCAAT/enhancer binding protein alpha (C/EBPα) may be associated with renal fibrosis. However, the precise role of C/EBPα in CKD progression remains unexplored.
We investigated the involvement of C/EBPα in CKD using two distinct mouse models induced by folic acid (FA) and unilateral ureteral obstruction (UUO). Additionally, we used RNA sequencing and KEGG analysis to identify potential downstream pathways governed by C/EBPα.
Cebpa knockout significantly shielded mice from renal fibrosis and reduced reactive oxygen species (ROS) levels in both the FA and UUO models. Primary tubular epithelial cells (PTECs) lacking Cebpa exhibited reduced apoptosis and ROS accumulation following treatment with TGF-β. RNA sequencing analysis suggested that apoptosis is among the primary pathways regulated by C/EBPα, and identified NADPH oxidoreductase 4 (NOX4) as a key protein upregulated upon C/EBPα induction (ICCB280). Treatment with l-Theanine, a potential NOX4 inhibitor, mitigated renal fibrosis and inflammation in both the FA and UUO mouse models.
Our study unveils a role for C/EBPα in suppressing renal fibrosis, mitigating ROS accumulation, and reducing cell apoptosis. Furthermore, we investigate whether these protective effects are mediated by C/EBPα's regulation of NOX4 expression. These findings present a promising therapeutic target for modulating ROS and apoptosis in renal tubular cells, potentially offering an approach to treating CKD and other fibrotic diseases.
慢性肾脏病(CKD)是一种常见的肾脏疾病,有多种危险因素。新出现的证据表明,转录因子 CCAAT/增强子结合蛋白α(C/EBPα)可能与肾纤维化有关。然而,C/EBPα 在 CKD 进展中的确切作用仍未被探索。
我们使用两种不同的叶酸(FA)和单侧输尿管梗阻(UUO)诱导的小鼠模型来研究 C/EBPα 在 CKD 中的作用。此外,我们还使用 RNA 测序和 KEGG 分析来鉴定由 C/EBPα 调控的潜在下游途径。
Cebpa 基因敲除显著保护小鼠免受肾纤维化的影响,并降低了 FA 和 UUO 模型中活性氧(ROS)的水平。缺乏 Cebpa 的原代肾小管上皮细胞(PTEC)在 TGF-β处理后,凋亡和 ROS 积累减少。RNA 测序分析表明,凋亡是 C/EBPα 调控的主要途径之一,并鉴定 NADPH 氧化还原酶 4(NOX4)为 C/EBPα 诱导时上调的关键蛋白(ICCB280)。用 L-茶氨酸(一种潜在的 NOX4 抑制剂)治疗,可减轻 FA 和 UUO 小鼠模型中的肾纤维化和炎症。
我们的研究揭示了 C/EBPα 在抑制肾纤维化、减轻 ROS 积累和减少细胞凋亡中的作用。此外,我们还研究了这些保护作用是否是由 C/EBPα 对 NOX4 表达的调节介导的。这些发现为调节肾小管细胞中的 ROS 和凋亡提供了一个有前途的治疗靶点,可能为治疗 CKD 和其他纤维化疾病提供一种方法。